| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CGP-60474 | GDSC1000 | pan-cancer | AAC | -0.056 | 0.3 |
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | -0.057 | 0.3 |
| mRNA | BRD-K24690302 | CTRPv2 | pan-cancer | AAC | -0.043 | 0.3 |
| mRNA | BRD-K55473186 | CTRPv2 | pan-cancer | AAC | -0.054 | 0.3 |
| mRNA | lenalidomide | FIMM | pan-cancer | AAC | 0.19 | 0.3 |
| mRNA | BRD-K45681478 | CTRPv2 | pan-cancer | AAC | -0.043 | 0.3 |
| mRNA | Dasatinib | GDSC1000 | pan-cancer | AAC | -0.053 | 0.3 |
| mRNA | vorinostat:carboplatin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.04 | 0.3 |
| mRNA | GW 441756 | GDSC1000 | pan-cancer | AAC | -0.037 | 0.3 |
| mRNA | Bleomycin | GDSC1000 | pan-cancer | AAC | 0.037 | 0.3 |